Identifying the specific structural features of metallothionein that regulate its ability to modulate astrogliosis. This project contributes directly to the Designated National Research Priority 2 and could potentially have a significant impact upon the broader Australian Community by identifying a novel and powerful therapeutic agent based upon metallothionein proteins with the ultimate aim of helping patients who have a brain injury or a neurodegenerative disease. It is important to note that ....Identifying the specific structural features of metallothionein that regulate its ability to modulate astrogliosis. This project contributes directly to the Designated National Research Priority 2 and could potentially have a significant impact upon the broader Australian Community by identifying a novel and powerful therapeutic agent based upon metallothionein proteins with the ultimate aim of helping patients who have a brain injury or a neurodegenerative disease. It is important to note that the partnership between UTAS and Bestenbalt LLC is a critical step in the development of these exciting research discoveries into commercially viable outcomes for the Australian Biotechnology Industry and the broader Australian community.Read moreRead less